Methods and devices for creation of communication between aorta and left atrium

Information

  • Patent Grant
  • 11986209
  • Patent Number
    11,986,209
  • Date Filed
    Thursday, February 25, 2021
    3 years ago
  • Date Issued
    Tuesday, May 21, 2024
    7 months ago
Abstract
Methods and devices are disclosed for the formation of a communication between the aorta and left atrium. The method includes introducing a puncturing device, positioning the device at a location along the aorta, and advancing the puncturing device to create a pathway. The method may include: a. via an inferior artery, advancing a perforating tip of the puncturing device towards the aorta; b. positioning the perforating tip adjacent a wall of the aorta, proximate the left atrium; and c. advancing the perforating tip to perforate through the wall of the aorta and then through a wall of the left atrium, to create a pathway between the aorta and the left atrium, wherein the creation of the pathway can be confirmed with at least one of fluoroscopy, electro-anatomical mapping, pressure measurement, contrast injection, and echocardiograph.
Description
TECHNICAL FIELD

The disclosure relates to systems and methods for creating a puncture in tissue. More specifically, the disclosure relates to a method and device to create a puncture (or a shunt) from the left atrium (LA) to aorta (Ao) or Ao to LA for communication between LA and Ao or Ao and LA.


BACKGROUND OF THE ART

It is often necessary to create perforations between various chambers of the heart and surrounding central vasculature to study etiology, pressure gradients, or enable end-therapy. For example, a left ventricular assist device (LVADs) have been widely used to help heart failure (HF) patients provide sufficient blood flow to peripheral organs, keeping patients alive as a bridge to transplantation or engendering return of native heart function. Percutaneous catheter LVAD support through connection of the left atrium (LA) to the aorta (LA-Ao) is used as a bridge to recovery in heart failure patients specifically because it is non-invasive to ventricular muscle. These LVAD catheters are currently track from the LA through the mitral valve to the LV through the aortic valve, to the aorta. Certain limitations may be associated with this conventional method, such as effusions, valve stenosis, hematoma, and vessel dissection.


SUMMARY

The following summary is intended to introduce the reader to various aspects of the detailed description, but not to define or delimit any invention.


There is a need to create a direct pathway/communication between the aorta and the left atrium while avoiding the mitral and aortic valves and the left ventricle.


Creating a pathway (communication) percutaneously between LA and Ao is significant as the end-therapy device, approach, and selected tools used to create the pathway play a role in optimal site-selection.


There is a need for a streamlined workflow using a puncture device, for example an atraumatic radio frequency (RF) guidewire, to reduce the number of exchanges and optimizes workflow while reducing complications during creation of a LA-Ao communication (e.g., effusions into pericardial space, vessel dissection, hematoma). The ability of the RF wire to navigate tortuous anatomy, puncture at the selected site through steering, deployment of an atraumatic anchor to support dilation and exchange of large sheath systems removes need for exchanging access devices for multiple devices. For example, the RF wire can function in each step of the procedure as a support guidewire.


Methods for creating a pathway between an aorta and a left atrium of a patient's heart are disclosed. According to some aspects, a method for creating a pathway between an aorta and a left atrium of a patient's heart includes: a. via a femoral venous access site and a right atrium, advancing a puncture assembly device towards an interatrial septum, wherein said puncture assembly device comprises a sheath, a dilator, and a flexible puncturing device; b. positioning a perforating tip of puncturing device adjacent an interatrial septum proximate a left atrium; c. advancing the perforating tip to perforate through the interatrial septum creating a pathway between the right atrium and left atrium; d. advancing the puncturing device to the left atrium; e. advancing the sheath and the dilator over the puncturing device through the septum and into the left atrium such that perforating tip of the puncturing device is aligned with a distal tip of the sheath and a distal tip of the dilator, forming said puncturing assembly; f. positioning the puncturing assembly at a target site within the left atrium to gain access to the aorta; and g. advancing the perforating tip of the puncturing device to perforate through the wall of the left atrium and then through a wall of the aorta, to create a pathway between the aorta and the left atrium.


In some examples, the puncturing device is a radiofrequency puncturing device, the perforating tip comprises a radiofrequency perforation electrode, and step g. comprises delivering radiofrequency energy from the radiofrequency perforation electrode while advancing the perforating tip.


In some examples, the method further includes: h. after step g., advancing a dilating tip of the dilator over the perforation device and through the pathway to dilate the pathway between the aorta and the left atrium; and step i. retracting the dilator through the sheath. The sheath can be selected from a steerable sheath, a fixed curve sheath, a small-bore steerable sheath, a large-bore steerable sheath, or a telescoping steerable sheath, and the dilator can be a flexible dilator.


In some examples, the method further includes: j. after step i., delivering a therapeutic device to the pathway via the sheath. Step j. can include positioning a shunt in the pathway or positioning a stent in the pathway.


In some examples, the method may further include: j. via the femoral venous, exchanging the sheath for a large-bore steerable sheath; and i. delivering a therapeutic device to the pathway via a large-bore steerable sheath.


In some examples, the method further includes: h. advancing a snare towards the aorta via an arterial access site (e.g., left or right femoral artery); and i. after step g., snaring the puncturing device with the snare. In some examples, the method further includes: j. after step i., retracting the snare to advance the puncturing device out of the body towards the arterial access site.


In some examples, the method further includes delivering a therapeutic device over the puncturing device towards the pathway, via the arterial access site.


In some examples, at least one of fluoroscopy, angiography, electro-anatomical mapping, intracardiac echocardiography, and transesophageal echocardiography is carried out concurrently with at least one of steps a. to g. In some examples, the method further includes confirming the creation of the pathway with at least one of fluoroscopy, electro-anatomical mapping, pressure measurement, contrast injection, and echocardiography.


According to some aspects, a method for creating a pathway between an aorta and a left atrium of a patient's heart includes: a. via an inferior artery, advancing a perforating tip of a puncturing device towards the aorta; b. positioning the perforating tip adjacent a wall of the aorta, proximate the left atrium; and c. advancing the perforating tip to perforate through the wall of the aorta and then through a wall of the left atrium, to create a pathway between the aorta and the left atrium, wherein the creation of the pathway can be confirmed with at least one of fluoroscopy, electro-anatomical mapping, pressure measurement, contrast injection, and echocardiography.


In some examples, the method further includes: d. via the inferior artery, advancing a dilator over the puncturing device to the aorta; e. after step c., advancing a dilating tip of the dilator over the perforation device and through the pathway to dilate the pathway between the aorta and the left atrium.


In some examples, the dilator can be a steerable dilator or a flexible dilator.


In some examples, the method may further includes: f. via the inferior artery, advancing a sheath over the dilator and the perforation device to the aorta and then to the left atrium; and g. after step e., retracting the dilator through the sheath.


In some examples, the dilator can be a hybrid dilator having features that provide a dual functionality of a sheath and a dilator, and the method may further includes: f. via the inferior artery, advancing the hybrid dilator over the perforation device to the aorta and then to the left atrium. More specifically, the hybrid dilator functions as a single device that removes the need for using conventional sheath/dilator assemblies and eliminates the need for an assembly, resulting in fewer exchanges, and reduced procedure times.


In some examples, the method further includes: d. advancing a snare towards the left atrium via a venous access site, a right atrium and then across an interatrial septum; and e. after step c., snaring the puncturing device with the snare. In some examples, the method further includes: f. after step e., retracting the snare to advance the perforating tip of the puncturing device out of the body towards the venous access site.


In some examples, the method further includes confirming the creation of the pathway between the left atrium and aorta, and/or crossing of the interatrial septum with at least one of fluoroscopy, electro-anatomical mapping (EAM), pressure differentials between the aorta and left atrium, contrast injection, or using intracardiac echocardiography (ICE) or transesophageal echocardiography (TEE).





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings are for illustrating examples of articles, methods, and apparatuses of the present disclosure and are not intended to be limiting. In the drawings:



FIGS. 1A and IB are a schematic view of a puncture assembly device in accordance with an embodiment of the present disclosure;



FIG. 2A is a perspective view of a dilator in accordance with an embodiment of the present disclosure;



FIG. 2B is a perspective view of a steerable sheath in accordance with an embodiment of the present disclosure;



FIG. 2C is a perspective view of a dilator in accordance with an alternate embodiment of the present disclosure;



FIGS. 3A-3C illustrate a dilator in use with a steerable sheath, in accordance with various embodiments of the present disclosure;



FIGS. 4A, 4B, 5, 6, 7A, 7B, 7C, 8A, and 8B illustrates the steps of a method for accessing an aorta via a left atrium, in accordance with an embodiment of the present disclosure;



FIGS. 9 and 10 illustrates the steps of a method for externalizing the puncture device, in accordance with an embodiment of the present disclosure;



FIGS. 11, 12, and 13 illustrates the steps of a method for accessing a left atrium via an aorta, in accordance with an embodiment of the present disclosure;



FIGS. 14 and 15 illustrates the steps of an alternative method for externalizing the puncture device in accordance with an alternative embodiment of the present disclosure;



FIG. 16 illustrates an example of a lasso catheter, in accordance with an embodiment of the present disclosure.





DETAILED DESCRIPTION

Various apparatuses or processes or compositions will be described below to provide an example of an embodiment of the claimed subject matter. No example described below limits any claim and any claim may cover processes or apparatuses or compositions that differ from those described below. The claims are not limited to apparatuses or processes or compositions having all the features of any one apparatus or process or composition described below or to features common to multiple or all of the apparatuses or processes or compositions described below. It is possible that an apparatus or process or composition described below is not an embodiment of any exclusive right granted by issuance of this patent application. Any subject matter described below and for which an exclusive right is not granted by issuance of this patent application may be the subject matter of another protective instrument, for example, a continuing patent application, and the applicants, inventors or owners do not intend to abandon, disclaim or dedicate to the public any such subject matter by its disclosure in this document.


Generally disclosed herein are methods for carrying out cardiac procedures, and more specifically, cardiac procedures in which a pathway (also referred to as a “communication”) is created between the aorta (e.g., the ascending aorta) and the left atrium (LA) of a patient. Such procedures can be carried out, for example, to allow for the insertion of a therapeutic device (e.g., a shunt or a stent) into the pathway, to treat heart defects.


In accordance with some embodiments of the present invention, some details of the devices are disclosed in application number PCT/IB2013/060287 (now publication number WO2015019132), and in application number PCT/IB2017/056777 (now publication number WO2018083599), which are incorporated herein by reference in its entirety.


In one broad aspect, embodiments of the present disclosure provides a method and device to create a communication or pathway from the left atrium (LA) to aorta (Ao) comprising, via a femoral venous access site, advancing a perforating tip of a puncture assembly towards the right atrium, accessing the left atrium via the septum and advancing the perforating tip to perforate through the wall of the left atrium and then through a wall of the aorta, to create a pathway between the aorta and the left atrium. The puncture assembly may include a sheath, a dilator, and a puncturing device usable alone or in combination and configured to facilitate tissue access and puncture at various anatomical locations from desired access sites. The puncturing device is atraumatic and may include one or more sections having sufficient flexibility for accessing the tissue site from the access site while retaining sufficient stiffness to perform one or more additional functions. For example, the puncturing device is capable of navigating vasculature through the femoral artery or femoral vein (for example when using for transseptal puncture) through to the aorta or LA, respectively.


The sheath (such as steerable sheath, fixed curve sheath, or two telescoping steerable sheaths instead of one for enhanced site-selection, small-bore steerable sheath <10 Fr, or large-bore steerable >15 Fr,) and the dilator are advanced over the guidewire (such as a radio frequency wire (RF wire), flexible/steerable needle, mechanical puncture wire, or bovie mechanical guidewire) to reach the target site, for example the left atrium or the aorta. After crossing the target site, the guidewire (for example, an RF wire) is snared, for example with a lasso catheter. The sheath may then be removed leaving the guide wire (such as an RF wire) within the LA for advancing end-therapy devices over the wire. In some instances, the access sheath may be advanced into the LA if the access sheath can support delivery of end therapy devices. In some cases, the selected end-therapy may not fit in the arterial vasculature chosen. A larger bore pathway to the target site can be created through the puncture to facilitate large-bore access into the LA-Ao and the selected end-therapy can then be tracked over the wire up the femoral artery or femoral vein and through the puncture.


In some embodiments, a vascular snare or lasso catheter is used. The lasso catheter comprise an elongated sheath connected to a handle at the proximal end. One or more loops are connected to the distal-end portion of the lasso catheter. The one or more loops may be opened and closed by manipulating the proximal end. When the one or more loops are open, a device may be ensnared within the loop. Successful ensnarement is usually confirmed through imaging such a fluoroscopy. Once ensnarement is achieved, the device can be retracted by the lasso.


In further instances, the wire may be externalized to support advancement of end-therapy devices. The access site to externalize out may be the femoral artery, common carotids, or femoral vein. With an externalized wire of sufficient length, it can be used to support stiffer end-therapy devices. In some cases, the selected end-therapy may not fit in the arterial vasculature chosen. To facilitate large-bore access into the LA-Ao communication (pathway) made, it can then be tracked over the RF wire up the femoral artery or femoral vein and through the puncture.


Access to the vasculature for creation of the communication (pathway) may be achieved from a femoral approach through the femoral vein or femoral artery. These specific embodiments can also be utilized for other approaches from central vasculature or for the creation of communication between other heart chambers and heart spaces with the intent of facilitating study or placement of end-therapy devices.


As a feature of this aspect, the site of puncture can be determined through several visualization methods, including but not limited to: (1) fluoroscopy through the use of RO (radiopaque) markers on the sheath and RF wire system; (2) electro-anatomical mapping for real-time placement of the RF wire and sheath with targets pre-determined on CT or in real-time (in real-time, the lasso catheter or guidewire with one or more electroanatomical (EAM) markers can be placed in the LA or Ao as a target for positioning and relative orientation; and (3) echogenic markers or features on either the RF wire or the supporting catheter can enable use of ICE or TEE for delineation of etiology and optimal target site to avoid damaging surrounding vasculature. Support and etiology of surrounding vasculature can also be used to interpret site selection. For creating the communication to or from the ascending aorta, for example, locating above the sinotubular junction (STJ) can aid in alignment with the LA. In cases where end-therapy sheaths need to be exchanged for the catheter system over the guidewire, such as an RF wire which is advanced during RF energy application, it can be useful to prevent un-intended dilation with the catheter system. While tenting tissue during site selection, the dilator (preferably sufficiently flexible dilator) can be retracted into the flexible sheath until the dilator and the sheath tip are aligned. As the flexible dilator easily conforms to the shape of the sheath, this can be completed without losing the optimal puncture location selected, resulting in decreased pressure on target tissue from sheath tip.


In some such examples, confirmation of access into Ao from LA or from the LA to Ao can be determined through several methods, including but not limited to: (1) fluoroscopy through the use of RO markers on the sheath and RF wire system; (2) electro-anatomical mapping for real-time placement of the guidewire, for example RF wire, and sheath with targets pre-determined on CT or in real-time (in real-time, a catheter or guidewire with one or more EAM markers can be placed in the LA or Ao as a target for positioning and relative orientation); (3) pressure differentials from the Ao to the LA and vice-versa; (4) contrast injection; and (5) echogenic markers or features on either the coil or the catheter can enable use of ICE or TEE for confirmation of location.


In an embodiment, an assembly is provided for puncturing tissue, where the assembly comprises a puncturing device for puncturing tissue. The puncturing device preferably comprises an atraumatic tip. Preferably, the atraumatic tip comprises an energy delivery device such as an electrode, capable of delivering radiofrequency energy to the target tissue, thereby creating a puncture in the tissue. In some examples, the puncturing device may be flexible, enabling the puncturing device to also be used as an exchange or guidewire. The assembly additionally comprises ancillary devices, such as a sheath and/or dilator, for supporting the flexible puncturing device. The sheath and/or dilator are operable to be selectively usable with the flexible puncturing device. In some examples, the flexible puncturing device is an energy-based device for delivering energy to the tip of the puncturing device in order to puncture the septum. In some embodiments, the flexible puncturing device has a lumen and one or more apertures. The lumen and aperture may combine to form a pressure transmitting lumen. The flexible puncturing device may be operable to be coupled to a pressure sensing mechanism, such as a pressure sensor, to measure the pressure transmitted through the lumen. In some embodiments, fluid (such as imaging or contrast fluid) is injected through the lumen and one or more apertures.


The assembly enables the flexible puncturing device to be usable independently from the ancillary devices as an exchange or guidewire during a portion of the procedure and to be usable in co-operation with other devices for puncturing tissue during another portion of the procedure. This reduces the number of exchanges needed by allowing the flexible puncturing device to be used for puncturing tissue, and as an exchange wire. The ancillary devices facilitate positioning of the energy delivery portion of the puncturing device against the desired target tissue location and may additionally reduce procedure complexity and enhance procedural efficiency.


Referring to FIGS. 1A and 1B, illustrations of a puncture assembly device 104 are provided that incorporates embodiments of devices that may be utilized during the procedure disclosed herein. The assembly 104 can be used for puncturing tissue such as interatrial septum and/or for creating a pathway or communication between left atrium and aorta (from left atrium (LA) to aorta (Ao) or Ao to LA). The assembly 104 comprises a tissue puncturing device 100, and ancillary device. In some examples, the ancillary device comprises a sheath 300 and a dilator 200 that are selectively usable with the tissue puncture device 100. In some examples, the tissue puncturing device 100 is substantially flexible, that can be maneuvered to the desired target location and/or that can be used as an exchange wire or guide wire without buckling or dislodging during exchanges. In some examples, the substantially flexible tissue puncture device 100 comprises a distal portion (section) 116 and a substantially atraumatic distal tip (perforating tip)112. The distal tip 112 may further comprise an energy delivery device 114 that is operable to deliver energy to puncture tissue. In some examples, the energy delivery device 114 can be an electrode, capable of delivering radiofrequency energy for puncturing a tissue. In an alternative embodiment, the substantially flexible tissue puncturing device 100 may comprise a sharp distal tip, which may be used to mechanically puncture the tissue.


In some examples, the distal portions (sections) 116 of the assembly 104 comprise a pigtail or J-tip configuration, as shown in FIGS. 1A and 1B. These configurations facilitate anchoring of the puncture device 100, for example after puncture. In some examples, the puncture device 100 comprises a radiofrequency (RF) wire that has an electrode at the distal tip (perforating tip)112 for delivering radiofrequency to puncture a tissue. In some examples, the RF wire is a flexible wire which is generally electrically insulated, save for selected distal regions with an electrode at the perforating tip 112. In an alternative embodiment, the puncture device 100 may comprise a sharp perforating tip 112 which relies on the application of mechanical force to puncture the tissue. In another embodiment, the puncture device 100 may be a steerable needle or a steerable power catheter.


In some embodiments of the puncture assembly device 104, the dilator 200 and sheath 300 each defines a respective lumen through which devices may be inserted (as shown in FIGS. 1A and 1B).


In some embodiments, the sheath 300 is a steerable sheath. In some embodiments, the steerable sheath is unidirectional, i.e., it allows deflection in a single direction. In other embodiments, a bi-directional sheath may be used. Alternately, in some embodiments, a fixed curve sheath may be utilized in place of an articulating sheath, depending on the tortuosity of the vasculature.


In some examples, the dilator 200 provides stiffness to the puncture assembly device 104 to facilitate force transmission to a distal end of the puncture assembly device 104. In other examples, the sheath 300 may be used with the dilator 200 to provide stiffness to the puncture assembly device 104 to enable force or torque to be transmitted to a distal end of the puncture device 100. In some such examples, the sheath 300 may be coupled to the dilator 200 which enables force and/or torque transmission using one or more of the components (i.e., the sheath 300 or the dilator 200). In other words, the user may just manipulate the sheath 300 or the dilator 200) and the puncture device 100 will follow the guidance and/or direction of the sheath 300 or the dilator 200.


In some embodiments, the dilator 200 is a flexible dilator used with a steerable sheath 300 to access a region of tissue within a patient's body. The steerable sheath 300, defining a lumen therethrough for receiving the dilator, has a range of deflection angles and to achieve a range of curvature upon actuation. The dilator 200 includes a substantially flexible or soft section that provides minimal resistance to deflection and is operable to be deflected under guidance to allow the dilator 200 to reach a desired site within a region of tissue within the patient's body to facilitate advancement of the distal end region. The flexible region allows the dilator 200 to conform to the curvature of the steerable sheath 300 that is achieved through actuation of the steerable sheath. In some embodiments, the distal end of the dilator 200 extends beyond the distal end of the sheath 300 to improve access to the target tissue within the patient's body.


In an embodiment, the dilator 200 is for use with an ancillary device such as a steerable sheath to access a region of tissue or tissue site within a patient's body, the steerable sheath defining a lumen therethrough for receiving the dilator and having a range of deflection angles. The dilator 200 comprises a rigid distal end region; and a flexible intermediate region. The dilator 200 can be configured in a such a way that, when the dilator is inserted into the lumen of the steerable sheath, the location of the flexible intermediate region corresponds to a location of a region of the steerable sheath that is amenable to deflection (also referred to as a “curvature-imparting region” or an “articulating region”). The dilator 200 may further comprise a rigid distal end region having a rigidity greater than the flexible intermediate region to enable the dilator to advance through tissue.


In the aforementioned embodiments, the dilator 200 is structured in such a way that, during use, the flexible intermediate region of the dilator is configured to provide minimal resistance to deflection so as to allow the deflectable region of the steerable sheath to deflect, thereby allowing the steerable sheath to reach a desired deflection angle from said range of deflection angles, to position the dilator rigid distal end region at a desired location within the region of tissue, allowing the dilator rigid distal end region to facilitate advancement of the dilator there-through.


In the embodiments, the dilator 200 described above are sufficiently flexible to allow the ancillary device to guide and position the dilator and/or additional devices in a wide array of patient anatomies. Embodiments of the dilator 200 accomplish this function by providing a flexible intermediate region having reduced stiffness. The location of the flexible region, when the dilator is inserted into/through the ancillary device, corresponds to a region of the ancillary device that is amenable to deflection or has a particular shape or curve, whereby the flexibility of the dilator at that location helps to ensure that the dilator does not substantially impair the ability of the ancillary device to retain, maintain or reach its intended shape or curvature. In some embodiments, the dilator 200, while being sufficiently flexible along the intermediate region, has sufficient stiffness along a distal end region to allow the dilator to be tracked or advanced across tissue for dilating a perforation or puncture at the desired target tissue site.


In accordance with another embodiment, as shown in FIG. 2A, a flexible dilator 200 is disclosed for use with a steerable sheath 300 (shown in FIG. 2B) to access a region of tissue within a patient's body. The steerable sheath 300 has a range of deflection angles and can achieve a range of curvatures upon actuation. Referring again to FIG. 2A, the dilator 200 comprises a dilator hub 202 that is coupled to an elongate member 204 that comprises regions of varying flexibility including an intermediate region 208 that terminates in a distal end region 206. In accordance with an embodiment of the present invention, the intermediate region 206 is a substantially flexible or soft section that provides minimal resistance to deflection and is operable to be deflected under guidance to allow the dilator 200 to reach a desired site within a region of tissue within the patient's body to facilitate advancement of the distal end region 206 there-through. The flexible intermediate region 208 allows the dilator 200 to conform to the curvature of the steerable sheath 300 that is achieved through actuation of the steerable sheath 300. Thus, in some embodiments, as outlined herein, the flexible intermediate region 208 does not inhibit the range of motion of the steerable sheath 300.


Additionally, the elongate member 204 of the dilator 200 further comprises a distal end region 206 that is formed distally adjacent to the flexible intermediate region 208, such that the flexible intermediate region 208 continues distally until (and terminates at) a proximal boundary or edge of the distal end region 206. In other words, the distal end region 206 extends proximally from the distal edge of the dilator 200 until a distal edge of the flexible intermediate region 208. The distal end region 206 has a stiffness or rigidity that is greater than the flexible intermediate region 208 to facilitate advancement of the dilator 200 through the tissue once the dilator 200 has been positioned at the desired tissue site, such as a desired puncture site. The stiff or substantially rigid distal end region 206 provides enhanced pushability and may prevent deformation thereof during advancement of the distal end region 206 through the tissue, for example at the puncture site to dilate the puncture site.


As outlined previously, the dilator 200 is usable with a steerable sheath 300 to access a region of tissue within a patient's body. The steerable sheath 300 may be of the type shown in FIG. 2B comprising an articulating portion or deflectable region 304 that is amenable to deflection upon actuation of a steerable actuation mechanism for example such as a knob of a handle 302. In use, the dilator 200 is inserted within the steerable sheath 300 such that a location or position of the flexible intermediate region 208 of the dilator 200 corresponds to the articulating portion or deflectable region 304 of the steerable sheath. This enables the steerable sheath 300 to reach its allowable range of curvatures or deflection, upon actuation, as minimal resistance is introduced by the dilator 200. In other words, the flexible intermediate region 208 of the dilator does not impart rigidity to the steerable sheath 300 as the dilator 200 is being steered by the steerable sheath 300. This enables the steerable sheath 300 to position the distal end region 206 of the dilator 200 at a desired target location within a region of tissue such as at a desired puncture location or site to enable the distal end region 206 to subsequently advance there-through while dilating the puncture site.


In a specific embodiment, an 8.5 French steerable sheath 300 with a 72 cm usable length and an 8.5 French dilator 200 with a usable length of 95 cm can be used. The dilator 200 tapers down to an outer diameter (OD) of about 0.046″ (about 1.2 mm) and an inner diameter (ID) of about 0.036″ (about 0.9 mm) at the distal tip.


In one embodiment, with reference to FIG. 2A, dilator 200 further comprises a proximal region 210 that forms a part of elongate member 204 of dilator 200. The proximal region 210 extends proximally from the flexible intermediate region 208. More specifically, the proximal region 210 extends proximally from a proximal boundary of the flexible intermediate region 208 and may extend until the dilator hub 202. In some embodiments the proximal region 210 may also be formed from a flexible material and exhibits flexibility. Alternatively, in other embodiments, as shown in FIG. 2C, the flexible intermediate region 208 may extend along the proximal region 210 and may include the proximal region 210. In some such embodiments, the flexible intermediate region 208 may have varying regions of flexibility.


With reference now to FIGS. 3A-3C, various embodiments of a steerable sheath 300 are shown with the dilator 200 inserted there-through. In some embodiments, once the dilator 200 has been inserted through the steerable sheath 300, the dilator 200 extends by a distance, for example about 3 cm, distally beyond the distal end or tip of the steerable sheath 300 (more specifically, beyond the distal end/edge of the steerable sheath 300). In some embodiments, the dilator extends by between about 2 cm to about 4 cm beyond the distal edge of the steerable sheath 300. In some embodiments, the steerable sheath 300 has a usable length 306 that is between about 71 cm to about 89 cm.


In one specific example, with reference now to FIG. 3A, the steerable sheath 300 is an 8.5 French unidirectional steerable sheath, that has a deflectable region or articulating portion 304 operable to adopt a curve S having an angle of about 180 degrees and a having a radius of curvature of about 8.5 mm. Alternatively, in the example as shown in FIG. 3B, the deflectable region or articulating portion 304 of the steerable sheath 300 is operable to adopt a curve M having a radius of curvature of about 11 mm. In another example as shown in FIG. 3C, the deflectable region or articulating portion 304 of the steerable sheath 300 is operable to adopt a curve L, having a radius of curvature equal to about 25 mm.


In one embodiment, the dilator 200 is usable with an ancillary device such that it allows the ancillary device to maintain or reach its intended shape or curvature in order to access a desired tissue site within a region of tissue within a patient's body. The dilator 200 may be of the type described herein above, that comprises a rigid distal end region 206 and a flexible intermediate region 208 terminating at the distal end region 206, with the rigid distal end region 206 having a rigidity greater than the flexible intermediate region 208 to enable the dilator 200 to advance through tissue. The dilator 200 is configured for use in conjunction with the ancillary device such that during use, the flexible intermediate region 208 corresponds to a region of the ancillary device that is functional for imparting or providing a curvature. In one particular example, the dilator 200 is advanced over or through the ancillary device such that such that during use the flexible intermediate region 208 of the dilator 200 does not affect the region of the ancillary device that is functional for imparting a curvature, allowing the ancillary device to substantially maintain or reach its intended position or shape in order to position the dilator rigid distal end region 206 at a desired location within the region of tissue.


In one such example, the ancillary device comprises a steerable device such as a sheath, catheter or guidewire that is steerable, where the ancillary device is functional for imparting a curvature by actuation of the ancillary device. When in use in conjunction with the dilator 200, the flexible intermediate region 208 of the dilator does not inhibit or prevent the ancillary device from reaching its intended curvature upon actuation to position the dilator distal end region 206 at a desired location. In another example, the ancillary device comprises a telescoping steerable sheath to enhance target site-selection.


Alternatively, in some embodiments, the ancillary device comprises a fixed curve device such as a fixed curve sheath that has a preformed curve. Similar to embodiments discussed previously herein, the fixed curve sheath is usable with the dilator 200 and during use the flexible intermediate region 208 of the dilator 200 does not affect the preformed curvature of the sheath, thus allowing the sheath to position the rigid distal end 206 of the dilator 200 at the desired location within the region of tissue. Furthermore, the use of the dilator 200, in accordance with an embodiment of the present invention, may prevent the need for over curving the sheath in anticipation of a substantial decrease in curvature of the sheath once the dilator 200 there-through.


In some embodiments, it may be desirable to use a hybrid dilator comprising features that provide a dual functionality of a sheath and a dilator. The hybrid dilator provides the smoothness of a standard dilator with the control of a steerable sheath. More specifically, the hybrid dilator functions as a single device that removes the need for using conventional sheath/dilator assemblies and eliminates the need for an assembly, resulting in less waste, fewer exchanges, and reduced procedure times. The hybrid dilator may comprise a sheath-like handle with familiar torque and tactile control. For example, the hybrid dilator comprises a proximal portion of a sheath hub with an actuation mechanism to steer the distal portion. The shaft extending from the hub is similar to that of a dilator wherein the distal tip comprises a tapered portion which may be used to dilate the puncture.


As outlined above, in some embodiments described herein above, the dilator 200 comprises varying regions of flexibility (i.e., rigid and flexible regions) to define a hybrid medical device. Since the dilator 200 comprises a substantially constant OD and ID and thus substantially constant wall thickness along its length, the behavior of the various regions, in terms of rigidity, is governed by the stiffness of the materials used. For example, the higher the stiffness of a material, the greater the rigidity, and the lower the stiffness of the material the lower the rigidity. Alternatively, in other embodiments, a single material may be used to form the dilator where the varying regions of flexibility are provided by varying the wall thickness along the respective regions. For example, an HDPE dilator may be provided with a relatively thin wall thickness along the flexible intermediate region and a relatively thicker wall thickness along the distal end region, in order to provide a dilator with the functionality described previously hereinabove.


In accordance with embodiments of the present invention, as described hereinabove, FIGS. 1A and 1B, 2A to 2C, and 3A to 3C illustrate embodiments of a medical device operable to be guided to a tissue site to puncture tissue and to function as a rail for installing devices thereupon. Such embodiments provide efficiencies to medical procedures in which they are utilized as they perform multiple functions and thereby reduce the amount of device exchanges that need to be performed. The “hybrid” medical devices further facilitate the access and puncture of a tissue site upon insertion at a particular access site on a patient's body.



FIGS. 1A and 1B illustrate embodiments of a substantially flexible energy based puncturing device such as an RF wire that is sufficiently flexible to enable access to heart tissue, such as from the left atrium (LA) to aorta (Ao) or Ao to LA for communication between LA and Ao or Ao and LA or a septum, from, for example, a transhepatic approach. An active region at the distal tip (perforating tip) 112 is operable to deliver energy for puncturing tissue (such as interatrial septum or a tissue between aorta and left atrium to create a puncture site therethrough which the RF wire can be advanced, for example to enter the left atrium from right atrium). In a specific embodiment the RF wire has an outer diameter (OD) of 0.035″ and a wire length of 180 cm. In another example, the RF wire has an outer diameter (OD) of 0.032″. In a further example, the RF wire has a radiopaque marker.



FIG. 1A shows a specific embodiment of a pigtail RF wire where the distal section 116 is biased to form a coil for anchoring the RF wire beyond the puncture site. FIG. 1B shows an example of a J-tip RF wire where the distal section 116 substantially forms a “J”. In some examples, when distal section 116 is advanced out of a dilator and beyond the septum or aorta, the biased curves act as an anchor in the left atrium, providing a rail into the left atrium. In an alternative embodiment, the distal portion of the RF wire may comprise an anchoring element which would help anchor the RF wire at a desired location.


Creating Pathway (Communication) Between the Left Atrium and Aorta via Inferior Approach


Access to the vasculature for creation of the pathway is achieved from inferior approach through the right atrium and then the interatrial septum. The vasculature may be accessed using traditional access procedures, such as the Seldinger technique, with the placement of a hemostatic valve (known and used in medical procedures requiring the insertion of a catheter into the vascular system of a patient). A puncturing device 100 may then be introduced into the patient's vasculature and then to the right atrium which would provide the most direct path to the first target puncture site of the interatrial septum. In the following embodiments, the puncturing device 100 is illustrated as a flexible puncturing device 100, such as a flexible puncturing guidewire; however, the puncturing device may be any alternative device used for puncturing tissue, such as a steerable needle, a steerable power catheter or a mechanical puncturing wire.


Referring now to FIGS. 4A to 16, a method for carrying out a cardiac procedure, and specifically for creating a pathway between an aorta and a left atrium via a venous access site (such as the femoral vein, the hepatic vein, etc.,) or arterial access site (e.g., left or right femoral artery) will be described. The method will be described with regard to the assembly device 104 shown in FIGS. 1A and 1B; however, the method is not limited to the assembly device 104.


In some examples of this method, FIGS. 4A, 4B, 5, 6, 7A, 7B, 7C, 8A, and 8B illustrates steps in which a pathway (communication) is created between left atrium and aorta via a venous access site (via the femoral vein)—that is, the left atrium can be approached via inferior vena cava (IVC) 706, the right atrium 704—for creating transseptal perforation and advancing to the left atrium 512, and then a perforation can be created in the wall of the left atrium (adjacent to ascending aorta) and then into the wall of aorta 504.


Referring to FIG. 4A, as a first step, the inferior vena cava (IVC) 706 is percutaneously accessed (e.g., using a procedure such as a Seldinger technique) and the perforating tip (distal tip) 112 of the puncturing device 100 can be advanced into the right atrium and towards the interatrial septum 702. The puncturing device 100 is a flexible puncturing device 100, such as a flexible puncturing guidewire; however, the puncturing device 100 may be any alternative device used for puncturing tissue, such as a steerable needle, a steerable power catheter or a mechanical puncturing wire. The assembly 104 of the sheath 300, dilator 200, and flexible puncturing device 100 are positioned within the right atrium and directed to a target site of interatrial septum. Once the assembly 104 is directed at the target puncturing site of the septum, the assembly 104 may tent the interatrial septum 702.


Referring to FIG. 4B, radiofrequency energy is then applied to the flexible puncturing device 100 and delivered to the distal tip (perforating tip) 112 (not shown) via the energy delivery device 114 for puncturing the septum thereby creating a hole or pathway in the interatrial septum 702 between the right atrium and left atrium. The flexible puncturing device 100 is advanced through the transseptal perforation at location into the left atrium. Alternatively, the puncturing device 100 may comprise a sharp distal tip 112 which may be used to mechanically puncture the interatrial septum 702.


With the flexible puncturing device 100 situated within the left atrium 512, the dilator 200 and the sheath 300 are advanced along flexible puncturing device 100 into the left atrium 512 until the distal tip of the flexible puncturing device 100 is aligned with the distal tip of the dilator 200, as shown in FIG. 5. In some examples, the dilator 200 may be advanced first, over the flexible puncturing device 100 through the puncture site to dilate the tissue and enlarge the puncture site for smooth advancement of the sheath 300 over the dilator 200.


In some examples, the target site of the transseptal perforation, advancement of the of puncturing device 100 from right atrium to left atrium, and the position of the perforating tip 112 of puncturing device 100 can be confirmed using fluoroscopy (e.g. in examples wherein the puncturing device 100 or the assembly 104 includes one or more radiopaque markers or features), angiography, electro-anatomical mapping (EAM) (e.g. to confirm real-time positioning of the perforating tip 112 using real-time or pre-determined computerized tomography data, in conjunction with the assembly 104 or guidewire with one or more EAM markers in the right atrium 704), intracardiac and/or transesophageal echocardiography (ICE and/or TEE) (e.g. using echogenic markers or features on the puncturing device 100).


Referring to FIG. 6, as a next step (or earlier or later in the method, for example prior to the previous steps), a mechanical guidewire 560 can be placed into the ascending aorta 504 from an arterial access site (not shown). For this step, the left or right femoral artery can be percutaneously accessed (e.g., using a procedure such as a Seldinger technique). The arterial access site can be inferior or superior to the ascending aorta. The guidewire 560 can then be exchanged for a lasso catheter 600 (exemplified in FIG. 16) having a snaring loop 570 (as shown in FIG. 7A). Preferably, the snare loop 570 is aligned to approximate the Sino-Tublar Junction (STJ) 510 above the aortic valve.


Referring to FIG. 7B, the assembly 104 of the sheath 300, dilator 200, and flexible puncturing device 100 are positioned within the left atrium 512 and directed towards the ascending aorta 504 and the puncturing target site. For example, the target site to puncture between the left atrium 512 and aorta 504 can preferably be above the Sino-Tubular Junction (STJ) 510 (as shown in FIG. 7A) which is situated above the aortic valve. In this position, the ascending aorta 504 is apposed to the left atrium 512. In this position, a space still exists between the ascending aorta 504 and left atrium 512, called the Transverse Pericardial Sinus (TPS) 525, within the pericardial space (as shown in FIG. 7C), but it is considered “virtual” or small. Support and etiology of surrounding vasculature may be used to determine an appropriate target site selection. For example, the sino-tubular junction (STJ) 510, shown in FIG. 7A, may act as an anatomical landmark and aid in positioning the assembly 104 towards the left atrium wall 575, adjacent the ascending aorta wall 514. As it would be known in the art, more superiorly into the ascending aorta 504, the aortic wall and left atrium are not apposed to each other as the aorta loops around the pulmonic trunk. After looping behind the pulmonic trunk, the aorta is referred to the “descending” aorta and apposes the left atrium again. As such, another potential puncture site is between the descending aorta 508 and left atrium free wall 575.


Once the assembly 104 is directed at the target puncturing site (as in FIG. 7B), the assembly 104 tents the tissue 516 between the left atrium wall 575 and the ascending aorta wall 514 (as seen in FIG. 7C). In order to avoid inadvertent dilation with the assembly, the dilator 200 may be retracted into the sheath 300 until the dilator 200 and sheath 300 tip are aligned; thus, the dilator 200 would still provide support to the flexible puncturing device 100 without losing the optimal puncture location. In some examples, the position of the assembly 104 may be observed using any suitable means, as previously described.


Referring to FIG. 8A, radiofrequency energy is applied to the flexible puncturing device 100 and delivered to the distal tip (perforating tip) 112 via the energy delivery device 114 for puncturing both the left atrium wall 575 and aortic wall 514. The flexible puncturing device 100 can then be advanced during energy application, creating a pathway or a hole and to allow fluid communication between the left atrium 512 and aorta 504. In some examples, creation of the pathway can be confirmed using fluoroscopy, electro-anatomical mapping, pressure measurement, contrast injection, and intracardiac and/or transesophageal echocardiography. The hole remains patent due to the puncturing device 100 (such as RF wire) occluding the hole and blood is prevented from leaking into the Transverse Pericardial Sinus 525 due to the occlusion by the device. Until the physician is ready to dilate the hole to place end therapy devices, it is preferable to not immediately dilate with the sheath and dilator assembly.


Referring to FIGS. 8A and 8B, the snare 570 of lasso catheter 600 can then be used to capture the distal end of the flexible puncturing device 100, by retraction of the snare loop into the lasso catheter sheath and “closing” on the distal end of the flexible puncturing device 100. The snare 570 can then be retracted to advance the puncturing device 100 towards the arterial access site as shown in FIG. 9 (e.g., left or right femoral artery, not shown), optionally to externalize the distal end of the flexible puncturing device 100.


Alternatively, the sheath 300 can be retracted towards femoral vein (for example, inferior vena cava 706) and a secondary sheath (e.g., a large bore sheath designed for therapeutic device delivery) can be advanced via the femoral vein. The secondary sheath can then be used to deliver a therapeutic device to the pathway.


In some embodiments, the flexible wire may be externalized to support advancement of end-therapy devices through the perforation between the aorta and the left atrium. Externalization of the flexible puncturing device 100 may be achieved through, for example, the patient's femoral artery or femoral vein. An externalized flexible wire having sufficient length may be used to support the introduction and positioning of stiffer therapeutic devices, such as end-therapy devices or end-therapy delivery devices. In this embodiment, the puncture device 100 would be dimensioned such that while the device is still accessible from the inferior entry point (for example, inferior vena cava 706) it is also externalized via the arterial access (e.g., left or right femoral artery). By allowing both ends of the puncture device 100 to be simultaneously secured by the user, the puncture device may act as a stiff support track allowing advancement of end-therapy devices through the femoral access.


In another embodiment, a method for creating a perforation from the aorta to the left atrium is illustrated in FIGS. 11 to 15. The methods disclosed herein involve the creation of a pathway between the aorta 504 and the left atrium 512 via an inferior approach—that is, the aorta can be approached via an inferior artery (e.g., the femoral artery), and a perforation can be created in the wall of the aorta and then into the wall of the left atrium. The methods disclosed result in externalizing the puncture device 100 by positioning a snare, such as a lasso catheter 600, in the left atrium 512 to capture the puncture device 100 once the puncture device enters the left atrium 512 from the aorta 504.


In accordance with a method aspect of this disclosure for creating a perforation from the aorta to the left atrium, the assembly 104 of the sheath 300, dilator 200, and flexible puncturing device 100 are advanced into the ascending aorta 504, as shown in FIG. 11, by first percutaneously accessing an inferior artery (for example, left or right femoral artery using a procedure such as a Seldinger technique) and advancing the perforating tip (distal tip) 112 of the puncturing device 100 into the inferior artery and towards the ascending aorta 504. The sheath 300 and the dilator 200 (such as a flexible dilator) are inserted over the puncturing device 100 until the distal tip of the flexible puncturing device 100 is aligned with the distal tip of the dilator 200. The assembly 104 of the sheath 300, dilator 200, and flexible puncturing device 100 are then positioned within the aorta, adjacent the perforation site (target site) against the aorta wall 514, as shown in FIG. 12. This can be achieved by steering the sheath 300 and/or dilator 200 (in examples wherein the sheath 300 and/or the dilator 200 are steerable), or by adjusting the position of the sheath 300 and/or dilator 200. This step can optionally be facilitated using fluoroscopy (e.g. in examples wherein the puncturing device 100 or the assembly 104 includes one or more radiopaque markers or features), angiography, electro-anatomical mapping (EAM) (e.g. to confirm real-time positioning of the perforating tip 112 using real-time or pre-determined computerized tomography data, in conjunction with a catheter or guidewire with one or more EAM markers in the aorta, intracardiac and/or transesophageal echocardiography (ICE and/or TEE) (e.g. using echogenic markers or features on the puncturing device 100 or on the sheath 300 and/or dilator 200). Alternatively, support and etiology of surrounding vasculature may be used to determine an appropriate target site selection. For example, the Sino-Tubular Junction (STJ) 510 (as shown in FIG. 7A) may act as an anatomical landmark and aid in positioning the assembly 104 towards the left atrium 512 to determine puncture site between the ascending aorta 504 and the left atrium 512. Alternatively, positioning the assembly near the left superior and inferior pulmonary veins may aid in creating communication between the descending aorta and the left atrium.


Referring to FIG. 12, the assembly 104 can then be directed at the puncturing site (site) and may tent the tissue 516 between the aorta wall 514 and left atrium wall 575. In some embodiments, the dilator 200 is retracted into the sheath 300, thereby enabling the sheath 300 to act as a stabilizer while positioning against the target tissue while enabling the dilator to provide support to the flexible puncturing device 100. This allows the forward force on the assembly 104 to be evenly distributed across the vessel (i.e., the aorta wall 514), decreasing the risk of inadvertent perforation of the tissue with the dilator or inadvertent dilation of the aorta wall 514 or left atrium wall 575. The deterrence of inadvertent puncture/dilation is important to prevent blood from leaking into the Transverse Pericardial Sinus 525, a space between the aortal wall 514 and left atrium wall 575 and is within the pericardial cavity of the heart.


Once the position of the target is confirmed, radiofrequency energy can then be applied to the flexible puncturing device 100 and delivered to the tissue via the energy delivery device 114 to create the perforation. The flexible puncturing device 100 is advanced during energy application, creating a puncture between the aorta and left atrium, forming a pathway for fluid communication between the aorta and the left atrium. In an alternative embodiment, the puncturing device 100 may comprise a sharp distal tip which may be used to mechanically puncture the tissue. Confirmation of target site and access into the left atrium from the aorta may be achieved through various methods described above, including fluoroscopy, electro-anatomical mapping (EAM), pressure differentials between the aorta and left atrium, contrast injection, or using intracardiac echocardiography (ICE) or transesophageal echocardiography (TEE).


Referring to FIG. 13, with the puncturing device 100 situated within the left atrium 512, the dilator 200 may be advanced, over the flexible puncturing device 100, through the puncture site to dilate the tissue and enlarge the puncture site. The sheath 300 and flexible dilator 200 may optionally be removed, leaving the flexible puncturing device 100 within the left atrium 512 to act as a guiderail for advancing end-therapy devices into the left atrium 512. In some examples, the sheath may be advanced into the left atrium, over the flexible puncturing device, if the access sheath is able to support the delivery of the end-therapy devices.


Referring to FIGS. 13 and 14, as a next step (or earlier or later in the method, for example prior to the previous steps—prior to advancing the assembly 104 towards the ascending aorta), a snare, such as a lasso catheter 600, can be advanced towards the left atrium 512. The lasso catheter 600 can be advanced, for example, via a femoral vein (for example, inferior vena cava 706). In the example shown, the lasso catheter 600 is advanced via the inferior vena cava 706, the right atrium 704, and to the left atrium 512 via a standard transseptal procedure (described above in this disclosure), until the lasso catheter 600 reaches the left atrium 512, as shown in FIG. 13. In some examples, a physician may first gain access to the femoral vein wherein a guidewire is inserted and advanced into the right atrium via the inferior vena cava 706. The guidewire may then act as a rail for the delivery of the assembly 104 (i.e., a transseptal needle, dilator, and sheath) which may be used to cross the septum. Alternatively, a puncturing guidewire (e.g., using radiofrequency energy or mechanical force) may be used instead of a standard guidewire. Using the transseptal assembly, the physician can gain access from the right atrium into the left atrium. The physician may remove the transseptal devices and advance a lasso catheter 600 into the left atrium 512. Preferably, this step may occur before the flexible puncture device 100, sheath 300 and dilator 200 have been advanced into the ascending aorta 504, such that the lasso catheter 600 is present within the left atrium 512 and acts as a “landing zone” when the puncturing device 100 enters the left atrium 512 from the aorta 504.


Referring to FIG. 14, with the lasso catheter 600 in the left atrium, the snare 570 of lasso catheter 600 can then be used to capture the distal end of the flexible puncturing device 100, by retraction of the snare loop into the lasso catheter sheath and “closing” on the distal end of the flexible puncturing device 100. The lasso catheter 600 may then retract back towards the right atrium 704, pulling the puncture device 100 along with it. At this point, the sheath 300 and dilator 200 may optionally be withdrawn from the aorta. The lasso catheter 600 can then be retracted to advance the puncturing device 100 towards the venous access site, as shown in FIG. 15, optionally to externalize the distal end of the flexible puncturing device 100. Optionally, the flexible puncturing device 100 can be “flossed” to enlarge the pathway. In this example, with the lasso catheter 600 and flexible puncturing device 100 externalized outside of the arterial access sites the physician now has an externalized rail to advance large delivery sheaths over-top of the device 100 or use puncture device 100 as a stiff guiderail for the delivery of end therapy devices. By allowing both ends of the puncture device to be simultaneously secured by the user, the puncture device may act as a stiff support track allowing advancement of end-therapy devices through the femoral access.


The present disclosure in various embodiments thus provides a system and method for the creation of a pathway or communication (including for example a perforation an atrial septum and perforation between an aorta and a left atrium). Visualization techniques as disclosed herein are advantageous for positioning the assembly 104 (puncturing device 100, dilator 200, sheath 300 and/or lasso catheter 600) within a patient's heart and for confirming that the desired ancillary device has entered into the aorta, the left atrium or right atrium subsequent to perforation or puncture. It should be noted, however, that a method of the present disclosure may be practised without any or all of pressure monitoring or visualization and is thus intended to comprise a method of creating a perforation/crossing in a tissue utilizing any intravascular approach. One of the motivations for creating a pathway or communication between the aorta and left atrium is to facilitate the study or placement of end-therapy devices. In some examples, the methods of the present disclosure may be used to create a pathway or communication between the aorta and the left atrium to position a stent, a shunt, or a pressure-sensitive catheter in the pathway. The method and system of the present disclosure may also be used to create large perforations between the atria and between the left atrium and aorta, as well as other perforations between other heart chambers and heart regions. All the applications/methods and devices disclosed herein are intended to be exemplary only and are not intended to limit the scope of the present disclosure in any way.


While the above description provides examples of one or more processes or apparatuses or compositions, it will be appreciated that other processes or apparatuses or compositions may be within the scope of the accompanying claims.


To the extent any amendments, characterizations, or other assertions previously made (in this or in any related patent applications or patents, including any parent, sibling, or child) with respect to any art, prior or otherwise, could be construed as a disclaimer of any subject matter supported by the present disclosure of this application, Applicant hereby rescinds and retracts such disclaimer. Applicant also respectfully submits that any prior art previously considered in any related patent applications or patents, including any parent, sibling, or child, may need to be re-visited.

Claims
  • 1. A method for creating a pathway between an aorta and a left atrium of a patient's heart, comprising: a. via a femoral venous access site and a right atrium, advancing a puncture assembly device towards an interatrial septum, wherein said puncture assembly device comprises a sheath, a dilator, and a flexible puncturing device;b. positioning a perforating tip of puncturing device adjacent an interatrial septum proximate a left atrium;c. advancing the perforating tip to perforate through the interatrial septum creating a pathway between the right atrium and left atrium;d. advancing the puncturing device to the left atrium;e. advancing the sheath and the dilator over the puncturing device through the septum and into the left atrium such that perforating tip of the puncturing device is aligned with a distal tip of the sheath and a distal tip of the dilator, forming said puncturing assembly;f. positioning the puncturing assembly at a target site within the left atrium to gain access to the aorta;g. advancing the perforating tip of the puncturing device to perforate through the wall of the left atrium and then through a wall of the aorta, to create a pathway between the aorta and the left atrium;h. advancing a snare towards the aorta via an arterial access site;i. snaring the puncturing device with the snare; andj. confirming the creation of the pathway between the aorta and the left atrium with at least one of fluoroscopy, electro-anatomical mapping, pressure measurement, contrast injection, and echocardiography.
  • 2. The method of claim 1, wherein the puncturing device is a radiofrequency puncturing device, the perforating tip comprises a radiofrequency perforation electrode, and step g. comprises delivering radiofrequency energy from the radiofrequency perforation electrode while advancing the perforating tip.
  • 3. The method of claim 1, further comprising: h. after step g., advancing a dilating tip of the dilator over the perforation device and through the pathway to dilate the pathway between the aorta and the left atrium; and step i. retracting the dilator through the sheath.
  • 4. The method of claim 3, wherein the sheath is selected from a steerable sheath, a fixed curve sheath, a small-bore steerable sheath, a large-bore steerable sheath, or a telescoping steerable sheath, and the dilator is a flexible dilator.
  • 5. The method of claim 3, further comprising: j. after step i., delivering a therapeutic device to the pathway via the sheath.
  • 6. The method of claim 5, wherein step j. comprises positioning a shunt or a stent in the pathway.
  • 7. The method of claim 1, further comprising: j. after step i., retracting the snare to advance the puncturing device out of the body towards the arterial access site.
  • 8. The method of claim 7, further comprising delivering a therapeutic device over the puncturing device towards the pathway, via the arterial access site.
  • 9. The method of claim 1, wherein at least one of fluoroscopy, angiography, electro-anatomical mapping, intracardiac echocardiography, and transesophageal echocardiography is carried out concurrently with at least one of steps a. to g.
  • 10. A method for creating a pathway between an aorta and a left atrium of a patient's heart, comprising: a. via a femoral venous access site and a right atrium, advancing a puncture assembly device towards an interatrial septum, wherein said puncture assembly device comprises a sheath, a dilator, and a flexible puncturing device;b. positioning a perforating tip of puncturing device adjacent an interatrial septum proximate a left atrium;c. advancing the perforating tip to perforate through the interatrial septum creating a pathway between the right atrium and left atrium;d. advancing the puncturing device to the left atrium;e. advancing the sheath and the dilator over the puncturing device through the septum and into the left atrium such that perforating tip of the puncturing device is aligned with a distal tip of the sheath and a distal tip of the dilator, forming said puncturing assembly;e. advancing the perforating tip of the puncturing device to perforate through the wall of the left atrium and then through a wall of the aorta, to create a pathway between the aorta and the left atrium;f. positioning the puncturing assembly at a target site within the left atrium to gain access to the aorta;g. advancing the perforating tip of the puncturing device to perforate through the wall of the left atrium and then through a wall of the aorta, to create a pathway between the aorta and the left atrium;h. advancing a dilating tip of the dilator over the perforation device and through the pathway to dilate the pathway between the aorta and the left atrium; and step i. retracting the dilator through the sheath;i. delivering a therapeutic device to the pathway via a large-bore steerable sheath; andj. exchanging the sheath for a large-bore steerable sheath.
  • 11. A method for creating a pathway between an aorta and a left atrium of a patient's heart, comprising: a. via a femoral venous access site and a right atrium, advancing a puncture assembly device towards an interatrial septum, wherein said puncture assembly device comprises a sheath, a dilator, and a flexible puncturing device;b. positioning a perforating tip of puncturing device adjacent an interatrial septum proximate a left atrium;c. advancing the perforating tip to perforate through the interatrial septum creating a pathway between the right atrium and left atrium;d. advancing the puncturing device to the left atrium;e. advancing the sheath and the dilator over the puncturing device through the septum and into the left atrium such that perforating tip of the puncturing device is aligned with a distal tip of the sheath and a distal tip of the dilator, forming said puncturing assembly;f. positioning the puncturing assembly at a target site within the left atrium to gain access to the aorta;g. advancing the perforating tip of the puncturing device to perforate through the wall of the left atrium and then through a wall of the aorta, to create a pathway between the aorta and the left atrium;h. advancing a snare towards the aorta via an arterial access site; andi. snaring the puncturing device with the snare.
US Referenced Citations (338)
Number Name Date Kind
175254 Oberly Mar 1876 A
827626 Gillet Jul 1906 A
848711 Weaver Apr 1907 A
1072954 Junn Sep 1913 A
1279654 Charlesworth Sep 1918 A
1918094 Geekas Jul 1933 A
1996986 Weinberg Apr 1935 A
2021989 De Master Nov 1935 A
2146636 Lipchow Feb 1939 A
3429574 Williams Feb 1969 A
3448739 Stark et al. Jun 1969 A
3575415 Fulp et al. Apr 1971 A
3595239 Petersen Jul 1971 A
4129129 Amrine Dec 1978 A
4244362 Anderson Jan 1981 A
4401124 Guess et al. Aug 1983 A
4639252 Kelly et al. Jan 1987 A
4641649 Walinsky et al. Feb 1987 A
4669467 Willett et al. Jun 1987 A
4682596 Bales et al. Jul 1987 A
4790311 Ruiz Dec 1988 A
4790809 Kuntz Dec 1988 A
4793350 Mar et al. Dec 1988 A
4807620 Strul et al. Feb 1989 A
4832048 Cohen May 1989 A
4840622 Hardy Jun 1989 A
4863441 Lindsay et al. Sep 1989 A
4884567 Elliott et al. Dec 1989 A
4892104 Ito et al. Jan 1990 A
4896671 Cunningham et al. Jan 1990 A
4928693 Goodin et al. May 1990 A
4936281 Stasz Jun 1990 A
4960410 Pinchuk Oct 1990 A
4977897 Hurwitz Dec 1990 A
4998933 Eggers et al. Mar 1991 A
5006119 Acker et al. Apr 1991 A
5019076 Yamanashi et al. May 1991 A
5047026 Rydell Sep 1991 A
5081997 Bosley et al. Jan 1992 A
5098392 Fleischhacker et al. Mar 1992 A
5098431 Rydell Mar 1992 A
5112048 Kienle May 1992 A
5154724 Andrews Oct 1992 A
5190528 Fonger Mar 1993 A
5201756 Horzewski et al. Apr 1993 A
5209741 Spaeth May 1993 A
5211183 Wilson May 1993 A
5221256 Mahurkar Jun 1993 A
5230349 Langberg Jul 1993 A
5281216 Klicek Jan 1994 A
5300068 Rosar et al. Apr 1994 A
5300069 Hunsberger et al. Apr 1994 A
5312341 Turi May 1994 A
5314418 Takano et al. May 1994 A
5318525 West et al. Jun 1994 A
5327905 Avitall Jul 1994 A
5364393 Auth et al. Nov 1994 A
5372596 Klicek et al. Dec 1994 A
5380304 Parker Jan 1995 A
5395341 Slater Mar 1995 A
5397304 Truckai Mar 1995 A
5403338 Milo Apr 1995 A
5423809 Klicek Jun 1995 A
5425382 Golden et al. Jun 1995 A
5490859 Mische et al. Feb 1996 A
5497774 Swartz et al. Mar 1996 A
5499975 Cope et al. Mar 1996 A
5507751 Goode et al. Apr 1996 A
5509411 Littmann et al. Apr 1996 A
5540681 Strul et al. Jul 1996 A
5545200 West et al. Aug 1996 A
5555618 Winkler Sep 1996 A
5571088 Lennox et al. Nov 1996 A
5575766 Swartz et al. Nov 1996 A
5575772 Lennox Nov 1996 A
5599347 Hart et al. Feb 1997 A
5605162 Mirzaee et al. Feb 1997 A
5617878 Taheri Apr 1997 A
5622169 Golden et al. Apr 1997 A
5624430 Eton et al. Apr 1997 A
5667488 Lundquist et al. Sep 1997 A
5673695 McGee et al. Oct 1997 A
5674208 Berg et al. Oct 1997 A
5683366 Eggers et al. Nov 1997 A
5720744 Eggleston et al. Feb 1998 A
5741249 Moss et al. Apr 1998 A
5766135 Terwilliger Jun 1998 A
5779688 Imran et al. Jul 1998 A
5810764 Eggers et al. Sep 1998 A
5814028 Swartz et al. Sep 1998 A
5830214 Flom et al. Nov 1998 A
5836875 Webster, Jr. Nov 1998 A
5849011 Jones et al. Dec 1998 A
5851210 Torossian Dec 1998 A
5885227 Finlayson Mar 1999 A
5888201 Stinson et al. Mar 1999 A
5893848 Negus et al. Apr 1999 A
5893885 Webster, Jr. Apr 1999 A
5904679 Clayman May 1999 A
5916210 Winston Jun 1999 A
5921957 Killion et al. Jul 1999 A
5931818 Werp et al. Aug 1999 A
5944023 Johnson et al. Aug 1999 A
5951482 Winston et al. Sep 1999 A
5957842 Littmann et al. Sep 1999 A
5964757 Ponzi Oct 1999 A
5967976 Larsen et al. Oct 1999 A
5989276 Houser et al. Nov 1999 A
6007555 Devine Dec 1999 A
6009877 Edwards Jan 2000 A
6013072 Winston et al. Jan 2000 A
6017340 Cassidy et al. Jan 2000 A
6018676 Davis et al. Jan 2000 A
6030380 Auth et al. Feb 2000 A
6032674 Eggers et al. Mar 2000 A
6036677 Javier, Jr. et al. Mar 2000 A
6048349 Winston et al. Apr 2000 A
6053870 Fulton, III Apr 2000 A
6053904 Scribner et al. Apr 2000 A
6056747 Saadat et al. May 2000 A
6063093 Winston et al. May 2000 A
6093185 Ellis et al. Jul 2000 A
6106515 Winston et al. Aug 2000 A
6106520 Laufer et al. Aug 2000 A
6117131 Taylor Sep 2000 A
6142992 Cheng et al. Nov 2000 A
6146380 Racz et al. Nov 2000 A
6155264 Ressemann et al. Dec 2000 A
6156031 Aita et al. Dec 2000 A
6171305 Sherman Jan 2001 B1
6179824 Eggers et al. Jan 2001 B1
6193676 Winston et al. Feb 2001 B1
6193715 Wrublewski et al. Feb 2001 B1
6210408 Chandrasekaran et al. Apr 2001 B1
6217575 Devore et al. Apr 2001 B1
6221061 Engelson et al. Apr 2001 B1
6228076 Winston et al. May 2001 B1
6245054 Fuimaono et al. Jun 2001 B1
6267758 Daw et al. Jul 2001 B1
6270476 Santoianni Aug 2001 B1
6283983 Makower et al. Sep 2001 B1
6292678 Hall et al. Sep 2001 B1
6293945 Parins et al. Sep 2001 B1
6296615 Brockway et al. Oct 2001 B1
6296636 Cheng et al. Oct 2001 B1
6302898 Edwards et al. Oct 2001 B1
6304769 Arenson et al. Oct 2001 B1
6315777 Comben Nov 2001 B1
6328699 Eigler et al. Dec 2001 B1
6360128 Kordis et al. Mar 2002 B2
6364877 Goble et al. Apr 2002 B1
6385472 Hall et al. May 2002 B1
6394976 Winston et al. May 2002 B1
6395002 Ellman et al. May 2002 B1
6419674 Bowser et al. Jul 2002 B1
6428551 Hall et al. Aug 2002 B1
6450989 Dubrul et al. Sep 2002 B2
6475214 Moaddeb Nov 2002 B1
6485485 Winston et al. Nov 2002 B1
6508754 Liprie et al. Jan 2003 B1
6524303 Garibaldi Feb 2003 B1
6530923 Dubrul et al. Mar 2003 B1
6554827 Chandrasekaran et al. Apr 2003 B2
6562031 Chandrasekaran et al. May 2003 B2
6562049 Norlander et al. May 2003 B1
6565562 Shah et al. May 2003 B1
6607529 Jones et al. Aug 2003 B1
6632222 Edwards et al. Oct 2003 B1
6639999 Cookingham et al. Oct 2003 B1
6650923 Lesh et al. Nov 2003 B1
6651672 Roth Nov 2003 B2
6662034 Segner et al. Dec 2003 B2
6663621 Winston et al. Dec 2003 B1
6702811 Stewart et al. Mar 2004 B2
6709444 Makower Mar 2004 B1
6723052 Mills Apr 2004 B2
6733511 Hall et al. May 2004 B2
6740103 Hall et al. May 2004 B2
6752800 Winston et al. Jun 2004 B1
6755816 Ritter et al. Jun 2004 B2
6811544 Schaer Nov 2004 B2
6814733 Schwartz et al. Nov 2004 B2
6820614 Bonutti Nov 2004 B2
6834201 Gillies et al. Dec 2004 B2
6842639 Winston et al. Jan 2005 B1
6852109 Winston et al. Feb 2005 B2
6855143 Davison et al. Feb 2005 B2
6860856 Ward et al. Mar 2005 B2
6869431 Maguire et al. Mar 2005 B2
6911026 Hall et al. Jun 2005 B1
6951554 Johansen et al. Oct 2005 B2
6951555 Suresh et al. Oct 2005 B1
6955675 Jain Oct 2005 B2
6970732 Winston et al. Nov 2005 B2
6980843 Eng et al. Dec 2005 B2
7022131 Derowe Apr 2006 B1
7029470 Francischelli et al. Apr 2006 B2
7048733 Hartley et al. May 2006 B2
7056294 Khairkhahan et al. Jun 2006 B2
7083566 Tornes et al. Aug 2006 B2
7112197 Hartley et al. Sep 2006 B2
7335197 Sage et al. Feb 2008 B2
7618430 Scheib Nov 2009 B2
7651492 Wham Jan 2010 B2
7666203 Chanduszko et al. Feb 2010 B2
7678081 Whiting et al. Mar 2010 B2
7682360 Guerra Mar 2010 B2
7828796 Wong et al. Nov 2010 B2
7900928 Held et al. Mar 2011 B2
8192425 Mirza et al. Jun 2012 B2
8257323 Joseph et al. Sep 2012 B2
8337518 Nance et al. Dec 2012 B2
8388549 Paul et al. Mar 2013 B2
8500697 Kurth et al. Aug 2013 B2
9072872 Asleson et al. Jul 2015 B2
9757541 Haarer Sep 2017 B2
11339579 Stearns May 2022 B1
20010012934 Chandrasekaran et al. Aug 2001 A1
20010021867 Kordis et al. Sep 2001 A1
20010044591 Stevens et al. Nov 2001 A1
20010051790 Parker Dec 2001 A1
20020019644 Hastings et al. Feb 2002 A1
20020022781 McLntire et al. Feb 2002 A1
20020022836 Goble et al. Feb 2002 A1
20020035361 Houser et al. Mar 2002 A1
20020087153 Roschak et al. Jul 2002 A1
20020087156 Maguire et al. Jul 2002 A1
20020111618 Stewart et al. Aug 2002 A1
20020123749 Jain Sep 2002 A1
20020147485 Mamo et al. Oct 2002 A1
20020161424 Rapacki Oct 2002 A1
20020169377 Khairkhahan et al. Nov 2002 A1
20020188302 Berg et al. Dec 2002 A1
20020198521 Maguire Dec 2002 A1
20030032929 McGuckin Feb 2003 A1
20030040742 Underwood et al. Feb 2003 A1
20030144658 Schwartz et al. Jul 2003 A1
20030158480 Tornes et al. Aug 2003 A1
20030163153 Scheib Aug 2003 A1
20030208220 Worley et al. Nov 2003 A1
20030225392 McMichael et al. Dec 2003 A1
20040015162 McGaffigan Jan 2004 A1
20040024396 Eggers Feb 2004 A1
20040030328 Eggers et al. Feb 2004 A1
20040044350 Martin et al. Mar 2004 A1
20040073243 Sepetka et al. Apr 2004 A1
20040077948 Violante et al. Apr 2004 A1
20040116851 Johansen et al. Jun 2004 A1
20040127963 Uchida et al. Jul 2004 A1
20040133113 Krishnan Jul 2004 A1
20040133130 Ferry et al. Jul 2004 A1
20040143256 Bednarek Jul 2004 A1
20040147950 Mueller et al. Jul 2004 A1
20040181213 Gondo Sep 2004 A1
20040230188 Cioanta et al. Nov 2004 A1
20050004585 Hall et al. Jan 2005 A1
20050010208 Winston et al. Jan 2005 A1
20050049628 Schweikert et al. Mar 2005 A1
20050059966 McClurken et al. Mar 2005 A1
20050065507 Hartley et al. Mar 2005 A1
20050085806 Auge et al. Apr 2005 A1
20050096529 Cooper et al. May 2005 A1
20050119556 Gillies et al. Jun 2005 A1
20050137527 Kunin Jun 2005 A1
20050149012 Penny et al. Jul 2005 A1
20050203504 Wham et al. Sep 2005 A1
20050203507 Truckai et al. Sep 2005 A1
20050261607 Johansen et al. Nov 2005 A1
20050288631 Lewis et al. Dec 2005 A1
20060041253 Newton et al. Feb 2006 A1
20060074398 Whiting et al. Apr 2006 A1
20060079769 Whiting et al. Apr 2006 A1
20060079787 Whiting et al. Apr 2006 A1
20060079884 Manzo et al. Apr 2006 A1
20060085054 Zikorus et al. Apr 2006 A1
20060089638 Carmel et al. Apr 2006 A1
20060106375 Werneth et al. May 2006 A1
20060135962 Kick et al. Jun 2006 A1
20060142756 Davies et al. Jun 2006 A1
20060189972 Grossman Aug 2006 A1
20060241586 Wilk Oct 2006 A1
20060247672 Vidlund et al. Nov 2006 A1
20060264927 Ryan Nov 2006 A1
20060276710 Krishnan Dec 2006 A1
20070060879 Weitzner et al. Mar 2007 A1
20070066975 Wong et al. Mar 2007 A1
20070118099 Trout, III May 2007 A1
20070123964 Davies et al. May 2007 A1
20070167775 Kochavi et al. Jul 2007 A1
20070185522 Davies et al. Aug 2007 A1
20070208256 Marilla Sep 2007 A1
20070225681 House Sep 2007 A1
20070270791 Wang et al. Nov 2007 A1
20080039865 Shaher et al. Feb 2008 A1
20080042360 Veikley Feb 2008 A1
20080086120 Mirza et al. Apr 2008 A1
20080097213 Carlson et al. Apr 2008 A1
20080108987 Bruszewski et al. May 2008 A1
20080146918 Magnin et al. Jun 2008 A1
20080171934 Greenan et al. Jul 2008 A1
20080208121 Youssef et al. Aug 2008 A1
20080243081 Nance et al. Oct 2008 A1
20080243222 Schafersman et al. Oct 2008 A1
20080275439 Francischelli et al. Nov 2008 A1
20090105742 Kurth et al. Apr 2009 A1
20090138009 Viswanathan et al. May 2009 A1
20090163850 Betts et al. Jun 2009 A1
20090177114 Chin et al. Jul 2009 A1
20090264977 Bruszewski et al. Oct 2009 A1
20100022948 Wilson et al. Jan 2010 A1
20100087789 Leeflang et al. Apr 2010 A1
20100125282 Machek et al. May 2010 A1
20100168684 Ryan Jul 2010 A1
20100179632 Bruszewski et al. Jul 2010 A1
20100191142 Paul et al. Jul 2010 A1
20100194047 Sauerwine Aug 2010 A1
20100249908 Chau et al. Nov 2010 A1
20110046619 Ducharme Feb 2011 A1
20110087261 Wittkampf Apr 2011 A1
20110130619 Whisenant Jun 2011 A1
20110130752 Ollivier Jun 2011 A1
20110152716 Chudzik et al. Jun 2011 A1
20110160592 Mitchell Jun 2011 A1
20110190763 Urban et al. Aug 2011 A1
20120109079 Asleson May 2012 A1
20120232546 Mirza et al. Sep 2012 A1
20120265055 Melsheimer et al. Oct 2012 A1
20120330156 Brown et al. Dec 2012 A1
20130184551 Paganelli et al. Jul 2013 A1
20130184735 Fischell et al. Jul 2013 A1
20130282084 Mathur et al. Oct 2013 A1
20140206987 Urbanski et al. Jul 2014 A1
20140296769 Hyde et al. Oct 2014 A1
20150157353 Lenker et al. Jun 2015 A1
20160175009 Davies Jun 2016 A1
20160220741 Garrison et al. Aug 2016 A1
20190021763 Zhou et al. Jan 2019 A1
20190247035 Gittard et al. Aug 2019 A1
Foreign Referenced Citations (15)
Number Date Country
2550988 Jan 2013 EP
3064246 Sep 2016 EP
2002532164 Oct 2002 JP
2007510458 Apr 2007 JP
2009537255 Oct 2009 JP
2010227580 Oct 2010 JP
2011206179 Oct 2011 JP
2015504328 Feb 2015 JP
2016530928 Oct 2016 JP
2005065562 Jul 2005 WO
2008066557 Jun 2008 WO
2008079828 Jul 2008 WO
2011014496 Feb 2011 WO
2013101632 Jul 2013 WO
2014182969 Nov 2014 WO
Related Publications (1)
Number Date Country
20210259732 A1 Aug 2021 US
Provisional Applications (1)
Number Date Country
62981434 Feb 2020 US